Professor Robert Bristow
University of Manchester, UK
Professor Amato Giaccia
Stanford University, USA
Professor Fei-Fei Liu
University of Toronto, Canada
Dr. Bristow joined University of Manchester as Director of the Manchester Cancer Research Centre (MCRC) in August 2017 with a remit to developing a new cancer strategy and lead the continued growth of the MCRC. Working with scientific and clinical researchers, Dr. Bristow’s aim is to develop personalized medicine approaches for cancer patients across Manchester, the North West and worldwide. Dr. Bristow was previously a Clinician-Scientist and Professor within the Departments of Radiation Oncology and Medical Biophysics at the University of Toronto. As a Senior Scientist at the Princess Margaret Cancer Centre he treated genitourinary cancers. His primary research interests are in tumour hypoxia, DNA damage signaling and DNA repair in tumours, and the genomics of prostate cancer progression and cancer treatment response.
He is particularly interested in novel clinical trials that intensify cancer therapy to prostate cancer patients whose tumours harbor aggressive genetic changes and hypoxic sub-regions. Dr. Bristow is the lead PI for the Canadian component of the ICGC whole genome prostate cancer sequencing project (CPC-GENE) and serves on a number of Scientific Advisory Board and Committees for: Prostate Cancer Canada, the Prostate Cancer Foundation (USA), the Canadian Cancer Society Research Institute, the MOVEMBER Foundation, American Association for Cancer Research (AACR) and the American Society for Therapeutic Radiation Oncology (ASTRO).
He is Editor of the 5th Edition Basic Science of Oncology and has over 250 published papers and book chapters. He is twice a Canadian Foundation for Innovation (CFI) awardee. He was made a Canadian Cancer Society Research Scientist in 2004 and an ESTRO Honorary Fellow in 2011.
Dr. Amato J. Giaccia obtained his Ph.D. in Pathology/Molecular Biology from the University of Pennsylvania in Philadelphia. He is a Professor of Radiation Oncology, Associate Chair for Research & Director of the Division of Radiation & Cancer Biology in the Department of Radiation Oncology. He also is the Director of Basic Science at the Stanford Cancer Institute and heads the Radiation Biology Program in Stanford’s Cancer Center.
He was awarded an American Cancer Society Junior Faculty Research Award and the Michael Fry Award from the Radiation Research Society for his outstanding contributions on understanding the molecular mechanisms of resistance promoted by the tumor microenvironment. Additionally, he was the recipient of the 2013 ASTRO Gold Medal. In 2015, he was awarded an NIH R35 Outstanding Investigator Award and was inducted into the National Academy of Medicine. He co-authored the sixth & seventh editions of the textbook, “Radiation Biology for the Radiologist,” with Professor Eric Hall from Columbia. In addition, he is currently the “Jack, Lulu and Sam Willson Professor in Cancer Biology” in the Stanford University School of Medicine.
Dr. Fei-Fei Liu is the Chief of the Radiation Medicine Program at the Princess Margaret Cancer Center, and the Chair of the University of Toronto – Department of Radiation Oncology. Dr. Liu’s research program has been focused on investigating and developing novel molecular therapeutic strategies for human malignancies, delivered in conjunction with radiation therapy, along with investigating molecular aberrancies of several human malignancies including breast, and head/neck cancers. Recently, her laboratory has shifted its focus to unraveling the mechanisms, and identifying therapeutic strategies of radiation fibrosis and lymphedema, two important late normal tissue toxicities with significant functional morbidity.
Professor Charles Limoli
University of California, Irvine, USA
Dr Nori Nakamura
Radiation Effects Research Foundation, Japan
Dr. Charles Limoli is a Professor of Radiation Oncology and Vice Chair of Academic Affairs at the University of California, Irvine (UCI). Dr. Limoli received a B.S. degree in chemistry from MIT (1984) and a doctoral degree in Biomedical Sciences from UCSD (1994). His recent work has defined the functional consequences and mechanisms of radiation and chemotherapy-induced cognitive dysfunction, including the impact of cosmic radiation exposure on the brain. His lab has developed stem cell and extracellular vesicle based transplantation approaches, genetic and pharmacologic interventions able to significantly ameliorate cancer treatment associated cognitive deficits. Dr. Limoli has co-authored 116 peer reviewed manuscripts, 14 book chapters, was the past President of the Radiation Research Society (2017) and the Translational Scientist of the Year at UCI (2014). Dr. Limoli is funded by the NCI, NINDS, NASA and the DTRA.
Current position: Consultant at RERF
1969 BS, Mechanical Engeneering, Osaka University
1973 Doctorat d’Université, Paris-Sud, Orsay, France
1974 MS, Biological Science, Hiroshima University
1979 Ph D, Biological Science, Hiroshima University
1974 Research Associate, Department of Radiation Biophysics, University of Tokyo Medical School
1984 Research Associate, Department of Pathology, RERF
1989 Assistant Chief, Department of Radiobiology
1994 Assistant Chief, Department of Genetics
1998-2007 Chief, Department of Genetics
2004-2012 Chief Scientist
1991-1995 Editorial Borad, IJRB
2004-2006 Chief Editor, J Radiat Res
2008-2012 Editorial Board, Radiat Res
2009-2012 Member of ICRP Committee 1